keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin

keyword
https://www.readbyqxmd.com/read/28813196/hepatic-parenchymal-heterogeneity-as-a-marker-for-oxaliplatin-induced-sinusoidal-obstruction-syndrome-correlation-with-treatment-response-of-colorectal-cancer-liver-metastases
#1
Na Yeon Han, Beom Jin Park, Kyung Sook Yang, Min Ju Kim, Deuk Jae Sung, Ki Choon Sim, Sung Bum Cho
OBJECTIVE: The objective of our study was to evaluate the influence of oxaliplatin-based chemotherapy (OBC)-induced hepatic parenchymal heterogeneity detected on contrast-enhanced CT scans on response of liver metastasis. We chose to study hepatic parenchymal heterogeneity on the basis of the assumption that hepatic parenchymal heterogeneity may indicate the presence of chemotherapy-induced sinusoidal obstruction syndrome (SOS). MATERIALS AND METHODS: For this retrospective study, 104 patients with hepatic metastases from colorectal cancer (male-female ratio, 66:38; age range, 20-80 years) who had undergone OBC and serial CT studies were consecutively registered...
August 16, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28812173/melatonin-attenuates-pain-hypersensitivity-and-decreases-astrocyte-mediated-spinal-neuroinflammation-in-a-rat-model-of-oxaliplatin-induced-pain
#2
Ye-Song Wang, Yuan-Yuan Li, Wei Cui, Li-Bin Li, Zhao-Cai Zhang, Bao-Ping Tian, Gen-Sheng Zhang
Neuroinflammatory response in spinal dorsal horn has been demonstrated to be a critical factor in oxaliplatin-induced pain. Melatonin has been shown to have anti-inflammatory and anti-allodynia effects in both preclinical and clinical studies. In the present study, we investigated the role of systemic administration of melatonin on oxaliplatin-induced pain. Intraperitoneal (i.p.) injection with oxaliplatin induced significantly mechanical allodynia and thermal hyperalgesia. Melatonin (i.p.) significantly alleviated mechanical allodynia and thermal hyperalgesia in the oxaliplatin but not sham-treated rats...
August 15, 2017: Inflammation
https://www.readbyqxmd.com/read/28807738/observed-benefit-and-safety-of-aflibercept-in-elderly-patients-with-metastatic-colorectal-cancer-an-age-based-analysis-from-the-randomized-placebo-controlled-phase-iii-velour-trial
#3
Paul Ruff, Eric Van Cutsem, Radek Lakomy, Jana Prausova, Guy A van Hazel, Vladimir M Moiseyenko, Karen Soussan-Lazard, Emmanuelle Dochy, Emmanuelle Magherini, Teresa Macarulla, Demetris Papamichael
OBJECTIVES: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. METHODS: Efficacy and safety were analyzed by treatment arm and age (≥ or <65years)...
August 12, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28804273/influence-of-the-number-of-axial-bexarotene-ligands-on-the-cytotoxicity-of-pt-iv-analogs-of-oxaliplatin
#4
Yulia N Nosova, Ilia V Zenin, Varvara P Maximova, Ekaterina M Zhidkova, Kirill I Kirsanov, Ekaterina A Lesovaya, Anna A Lobas, Mikhail V Gorshkov, Olga N Kovaleva, Elena R Milaeva, Markus Galanski, Bernhard K Keppler, Alexey A Nazarov
We present the synthesis and cytotoxic potencies of new Pt(IV) complexes with bexarotene, an anticancer drug that induces cell differentiation and apoptosis via selective activation of retinoid X receptors. In these complexes bexarotene is positioned as an axial ligand. The complex of one bexarotene ligand attached to Pt(IV) oxaliplatin moiety was potent whereas its counterpart carrying two bexarotene ligands was inactive.
2017: Bioinorganic Chemistry and Applications
https://www.readbyqxmd.com/read/28803938/organoids-as-preclinical-models-to-improve-intraperitoneal-chemotherapy-effectiveness-for-colorectal-cancer-patients-with-peritoneal-metastases-preclinical-models-to-improve-hipec
#5
P Roy, C Canet-Jourdan, M Annereau, O Zajac, M Gelli, S Broutin, L Mercier, A Paci, F Lemare, M Ducreux, D Elias, D Malka, V Boige, D Goéré, F Jaulin
BACKGROUND: Peritoneal metastases (PM), corresponding to tumor implants into the peritoneal cavity, are associated with impaired prognosis and low responsiveness to systemic chemotherapy. A new therapeutic approach has dramatically changed the prognosis of patients with PM from colorectal cancer (CRC), consisting in the association of a complete cytoreductive surgery followed by intraperitoneal chemotherapy associated to hyperthermia (HIPEC). Many drugs have been administered intraperitoneally, but no clear consensus has been approved...
August 10, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28801995/inst-ox-05-024-first-line-gemcitabine-oxaliplatin-and-erlotinib-for-primary-hepatocellular-carcinoma-and-bile-duct-cancers-a-multicenter-phase-ii-trial
#6
Yehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, Ari D Baron, Pranshu Bansal, Yanis Boumber, Kim Steinberg, Sang-Joon Lee, Ed Bedrick, Ruofei Du, Fa Chyi Lee
Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor (TKI) with known activity against both. We sought to evaluate the efficacy of the combination G+O+E. Patients with either of the two diagnosis were treated in a phase II trial. Simons 2 stage design was used. A disease-control rate (DCR), complete response (CR) + partial response (PR)+ stable disease (SD) at 24 weeks of ≤20% and >40% (P0 and P1 of 0...
August 11, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28801547/early-changes-in-plasma-dna-levels-of-mutant-kras-as-a-sensitive-marker-of-response-to-chemotherapy-in-pancreatic-cancer
#7
Marzia Del Re, Caterina Vivaldi, Eleonora Rofi, Enrico Vasile, Mario Miccoli, Chiara Caparello, Paolo Davide d'Arienzo, Lorenzo Fornaro, Alfredo Falcone, Romano Danesi
Pancreatic cancer (PDAC) is still lacking of reliable markers to monitor tumor response. CA 19-9 is the only biomarker approved, despite it has several limitations in sensitivity and specificity. Since mutations of KRAS occur in more than 90% of tumors, its detection in circulating free tumor DNA (cftDNA) could represent a biomarker to monitor chemotherapy response. Twenty-seven advanced PDAC patients given first-line 5-fluorouracil, irinotecan and oxaliplatin or gemcitabine and nab-paclitaxel were enrolled...
August 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28800641/high-rbm3-expression-is-associated-with-an-improved-survival-and-oxaliplatin-response-in-patients-with-metastatic-colorectal-cancer
#8
Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard
BACKGROUND: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. METHODS: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients...
2017: PloS One
https://www.readbyqxmd.com/read/28782476/a-case-of-capecitabine-induced-hyperammonemia-in-a-patient-with-colon-cancer
#9
Wentong Fang, Yuanyuan Fu, Ji-Fu Wei
BACKGROUND: Hyperammonemia is an infrequent adverse drug reaction (ADR) of chemotherapy. A few cases of 5-fluorouracil (5-FU) related hyperammonemia have been reported. OBJECTIVE: However, hyperammonemia induced by capecitabine, an oral prodrug of 5-FU, has not been reported till date. A patient with colon cancer was treated with CapeOx(oxaliplatin 200mg, day 1; capecitabine 1.5g bid, days 1-14). On the fifth day of first cycle chemotherapy, she developed hyperammonemia(240 μmol/L) and psychiatric symptoms...
August 7, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28781787/combined-perioperative-eox-chemotherapy-and-postoperative-chemoradiotherapy-for-locally-advanced-gastric-cancer
#10
Qiushan He, Juan Zhao, Jia Yuan, Zhimin Gong, Tienan Yi
Currently, adjunctive therapy for gastric cancer is not standardized worldwide and the most effective combination of different modalities has not been clearly determined. The aim of the present study was to retrospectively analyze the efficacy and toxicity of the combination of perioperative epirubicin, capecitabine and oxaliplatin (EOX) chemotherapy and postoperative concurrent chemoradiotherapy in the treatment of locally advanced gastric cancer. A total of 41 patients with locally advanced gastric cancer who had undergone perioperative EOX chemotherapy and surgical resection followed by chemoradiotherapy, were assessed...
August 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28781785/effect-of-age-on-the-development-of-chemotherapy-associated-liver-injury-in-colorectal-cancer-liver-metastasis
#11
Taiichi Wakiya, Daisuke Kudo, Keinosuke Ishido, Norihisa Kimura, Yuta Yakoshi, Yoshikazu Toyoki, Hiroshi Kijima, Kenichi Hakamada
With the prolongation of the mean lifespan, the number of elderly individuals undergoing liver resection for colorectal cancer liver metastasis (CRLM) following chemotherapy has increased. However, the effect of age on the development of chemotherapy-associated liver injury (CALI) in CRLM remains unclear. The aim of the present study was to elucidate the effect of age on the development of CALI in CRLM. A total of 64 patients undergoing liver resection for CRLM following oxaliplatin-based chemotherapy (OBC) were investigated...
August 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#12
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28777427/paclitaxel-oxaliplatin-5-fluorouracil-and-leucovorin-combination-chemotherapy-in-patients-with-recurrent-or-metastatic-gastric-cancer
#13
Yan-Qin Lan, Ri-Ping Wu, Xiao-Bing Huang, Xin-Li Wang, Dong-Ta Zhong, Chuan-Yong Huang, Jin-Tian Song
PURPOSE: This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer. METHODS: One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m2 as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m2 as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle...
July 27, 2017: Tumori
https://www.readbyqxmd.com/read/28766482/self-reported-adherence-to-capecitabine-on-xelox-treatment-as-adjuvant-therapy-for-colorectal-cancer
#14
Kazuyoshi Kawakami, Takashi Yokokawa, Kazuo Sugita, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama
Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as adjuvant therapy for colorectal cancer. The main aim of this study was to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011 and April 30, 2015 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research...
August 1, 2017: Oncology Research
https://www.readbyqxmd.com/read/28765502/a-phase-ii-study-with-lead-in-safety-cohort-of-5-fluorouracil-oxaliplatin-and-lapatinib-in-combination-with-radiation-therapy-as-neoadjuvant-treatment-for-patients-with-localized-her2-positive-esophagogastric-adenocarcinomas
#15
Gregg Shepard, Edward R Arrowsmith, Patrick Murphy, John H Barton, James D Peyton, Mark Mainwaring, Laura Blakely, Noel A Maun, Johanna C Bendell
LESSONS LEARNED: Neoadjuvant 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2-positive esophagogastric adenocarcinoma.Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy. BACKGROUND: The optimal design of neoadjuvant chemoradiation for the treatment of localized esophagogastric cancers is the subject of much debate...
August 1, 2017: Oncologist
https://www.readbyqxmd.com/read/28762171/addition-of-an-antiangiogenic-therapy-bevacizumab-to-gemcitabine-plus-oxaliplatin-improves-survival-in-advanced-biliary-tract-cancers
#16
Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie-Anne Guillaumot, Catherine Brezault, Olivier Mir, François Goldwasser, Romain Coriat
Background The prognosis of patients with metastatic carcinoma of the biliary tract (mBTC) is poor and a systemic therapy with gemcitabine and platinum-based is the gold standard. The addition of bevacizumab to the chemotherapy might increase patients' survival. Our aim was to assess and compare the efficacy of GEMOX (gemcitabine and oxaliplatin regimen) plus bevacizumab to GEMOX alone in mBTC. Methods Patients with mBTC who received the GEMOX-bevacizumab (n = 32; Group A) or GEMOX (n = 25; Group B) regimen as first-line treatment were compared...
August 1, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28761750/european-medicines-agency-approval-summary-zaltrap-for-the-treatment-of-patients-with-oxaliplatin-resistant-metastatic-colorectal-cancer
#17
REVIEW
Stefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, Paolo Foggi, Mariapaola Caleno, Daniela Melchiorri, Iordanis Gravanis, Kyriaki Tzogani, Francesco Pignatti
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing regimen. Aflibercept is a recombinant fusion protein which blocks the activation of vascular endothelial growth factor (VEGF) receptors and the proliferation of endothelial cells, acting as a soluble decoy receptor that binds to VEGF-A with higher affinity than its native receptors, as well as placental growth factor and VEGF-B...
2017: ESMO Open
https://www.readbyqxmd.com/read/28761727/s-1-and-oxaliplatin-sox-plus-bevacizumab-versus-mfolfox6-plus-bevacizumab-as-first-line-treatment-for-patients-with-metastatic-colorectal-cancer-updated-overall-survival-analyses-of-the-open-label-non-inferiority-randomised-phase-iii-soft-study
#18
Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
OBJECTIVE: The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l-leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastatic colorectal cancer (mCRC). The overall survival (OS) data were immature at the time of the primary analysis. METHODS: A total of 512 patients were enrolled and randomly assigned to receive either mFOLFOX6 plus bevacizumab (5 mg/kg of bevacizumab, followed by 200 mg/m(2) of l-leucovorin given simultaneously with 85 mg/m(2) of oxaliplatin, followed by a 400 mg/m(2) bolus of 5-FU on day 1 and then 2400 mg/m(2) of 5-FU as an intravenous infusion over the course of 46 hours, every 2 weeks) or SOX plus bevacizumab (7...
2017: ESMO Open
https://www.readbyqxmd.com/read/28761726/phase-i-study-of-neoadjuvant-chemotherapy-with-s-1-and-oxaliplatin-for-locally-advanced-gastric-cancer-neo-g-sox-pi
#19
Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
BACKGROUND: The prognosis of locally advanced gastric cancer, such as clinical T4 disease, bulky nodal involvement, type 4 and large type 3 gastric cancer, remains unsatisfactory, even with D2 gastrectomy followed by adjuvant chemotherapy. One promising approach is neoadjuvant chemotherapy. Combination chemotherapy with S-1 and oxaliplatin (SOX) is recognised as a potentially promising regimen for gastric cancer. However, the use of neoadjuvant chemotherapy consisting of SOX for locally advanced gastric cancer has not been reported...
2017: ESMO Open
https://www.readbyqxmd.com/read/28760501/-hypersensitivity-to-platinum-salts-and-taxanes-the-value-of-skin-tests-and-tolerance-induction-procedures
#20
F Brault, J Waton, C Poreaux, J-L Schmutz, A Barbaud
AIM: The rate of hypersensitivity reactions to platinum salts (PS) and taxanes (TX) is on the increase. The aim of our study was to show the value of skin testing and efficacy of rapid drug desensitization. PATIENTS AND METHODS: This was a retrospective study conducted between January 2007 and February 2016 in patients consulting for immediate or delayed hypersensitivity to PS and TX. Skin prick tests (pT) and intradermal reaction tests (IDR) were performed according to the ENDA/EAACI recommendations...
July 28, 2017: Annales de Dermatologie et de Vénéréologie
keyword
keyword
73953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"